Oncodesign Precision Medicine Société anonyme's latest marketcap:
As of 08/12/2025, Oncodesign Precision Medicine Société anonyme's market capitalization has reached $9.28 M. According to our data, Oncodesign Precision Medicine Société anonyme is the 41320th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 9.28 M |
| Revenue (ttm) | 2.02 M |
| Net Income (ttm) | 7.33 M |
| Shares Out | 18.17 M |
| EPS (ttm) | 0 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/18/2025 |
Oncodesign Precision Medicine Société anonyme's yearly market capitalization.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/12/2025 | €7.96 M | $9.28 M | -40.48% | 41320 |
| 12/31/2024 | €12.97 M | $13.43 M | -56.74% | 36537 |
| 12/29/2023 | €29.99 M | $33.1 M | 155.14% | 30538 |
| 12/30/2022 | €11.75 M | $12.58 M | 34975 |
Company Profile
About Oncodesign Precision Medicine Société anonyme
Oncodesign Precision Medicine Société anonyme is a biopharmaceutical company specializing in precision medicine. Founded in 1995 and headquartered in Dijon, France, the company focuses on developing innovative therapies for challenging diseases.
Pipeline Highlights
- OPM-101: A RIPK2 inhibitor currently in Phase 1 clinical trials for inflammatory bowel disease.
- OPM-102: A novel cancer treatment in preclinical studies.
- OPM-201: A potential LRRK2 inhibitor in Phase 1 trials for Parkinson’s disease.
Additional Research & Collaborations
The company is also advancing therapies for pancreatic and other cancers. Additionally, Oncodesign has a strategic partnership with Navigo Proteins GmbH to discover and develop new systemic radiotheranostic agents.
Frequently Asked Questions
-
What is Oncodesign Precision Medicine Société anonyme's (EPA-ALOPM) current market cap?As of 08/12/2025, Oncodesign Precision Medicine Société anonyme (including the parent company, if applicable) has an estimated market capitalization of $9.28 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Oncodesign Precision Medicine Société anonyme (EPA-ALOPM) rank globally by market cap?Oncodesign Precision Medicine Société anonyme global market capitalization ranking is approximately 41320 as of 08/12/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.